Conferencia dictada en el XVII Congreso Latinoamericano de Alergia, Asma e Inmunología, Cartagena, 2012

1. Prof. Dr. Paolo Falagiani (1947 – 2011)

2. 1: Liccardi G, Passalacqua G, Salzillo A, Piccolo A, Falagiani P, Russo M, 13: Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for 25: Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, 40: Tripodi S, Falagiani P, Perinelli T, Dell'Omo F, Cristaldi A. Allergy to
Canonica GW, D'Amato G. Is sensitization to furry animals an independent allergic allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Canonica GW, Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived fishing bait. Allergy. 2002 Jul;57(7):653. PubMed PMID: 12100315.
phenotype in nonoccupationally exposed individuals? J Investig Allergol Clin Allergy Clin Immunol. 2008 May;40(1):22-9. PubMed PMID: 18700331. monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005
Immunol. 2011;21(2):137-41. PubMed PMID: 21462804. Nov;138(3):197-202. Epub 2005 Oct 3. PubMed PMID: 16205097.
41: Pocobelli D, Del Bono A, Venuti L, Falagiani P, Venuti A. Nasal immunotherapy
14: D'Anneo RW, Arena A, Gammeri E, Bruno ME, Falagiani P, Riva G, Leonardi S, La at constant dosage: a double-blind, placebo-controlled study in grass-allergic
2: Petrarca C, Lazzarin F, Pannellini T, Iezzi M, Braga M, Mistrello G, Falagiani Rosa M. Parietaria sublingual allergoid immunotherapy with a co-seasonal 26: Passalacqua G, Altrinetti V, Mariani G, Falagiani P, Mistrello G, Brizzolara rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2001;11(2):79-88. PubMed
P, Di Giampaolo L, Di Gioacchino M. Monomeric allergoid intragastric treatment schedule. Allergol Immunopathol (Madr). 2008 Mar-Apr;36(2):79-84. R, Canonica GW, Bagnasco M. Pharmacokinetics of radiolabelled Par j 1 PMID: 11642577.
administration induces local and systemic tolerogenic response involving PubMed PMID: 18479659. administered intranasally to allergic and healthy subjects. Clin Exp Allergy.
IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. Int J Immunopathol 2005 Jul;35(7):880-3. PubMed PMID: 16008673.
Pharmacol. 2010 Oct-Dec;23(4):1021-31. PubMed PMID: 21244752. 42: Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW,
15: Burastero SE, Mistrello G, Falagiani P, Paolucci C, Breda D, Roncarolo D, Passalacqua G. Safety of sublingual immunotherapy with monomeric allergoid in
Zanotta S, Monasterolo G, Rossi RE. Effect of sublingual immunotherapy with grass 27: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Why do lipid adults: multicenter post-marketing surveillance study. Allergy. 2001
3: Marogna M, Massolo A, Colombo F, Isella P, Bruno M, Falagiani P. Children monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 transfer protein-hypersensitive patients tolerate bean (and other legumes)? Int Oct;56(10):989-92. PubMed PMID: 11576079.
passive smoking jeopardises the efficacy of standard anti-allergic production. Ann Allergy Asthma Immunol. 2008 Apr;100(4):343-50. PubMed PMID: Arch Allergy Immunol. 2005 Jul;137(3):236-40. Epub 2005 Jun 13. PubMed PMID:
pharmacological therapy, while sublingual immunotherapy withstands. Allergol 18450120. 15956792.
Immunopathol (Madr). 2011 Mar-Apr;39(2):60-7. Epub 2011 Jan 7. PubMed PMID: 43: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. Allergy to
21216083. nonspecific lipid transfer proteins in Rosaceae: a comparative study of different
16: Falagiani P. Nickel hyposensitization: a literature review. Int J 28: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Detection of novel in vivo diagnostic methods. Ann Allergy Asthma Immunol. 2001 Jul;87(1):68-71.
Immunopathol Pharmacol. 2005 Oct-Dec;18(4 Suppl):3-5. Review. PubMed PMID: latex allergens associated with clinically relevant allergy to plant-derived PubMed PMID: 11476467.
4: Marogna M, Colombo F, Cerra C, Bruno M, Massolo A, Canonica GW, Falagiani P, 17761097. foods. J Allergy Clin Immunol. 2005 Jun;115(6):1312-4. PubMed PMID: 15940153.
Passalacqua G. The clinical efficacy of a sublingual monomeric allergoid at
different maintenance doses: a randomized controlled trial. Int J Immunopathol 44: Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G,
Pharmacol. 2010 Jul-Sep;23(3):937-45. PubMed PMID: 20943066. 17: Mistrello G, Harfi H, Roncarolo D, Kwaasi A, Zanoni D, Falagiani P, Panzani 29: Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun;56(6):578. PubMed PMID:
R. Date palm pollen allergoid: characterization of its chemical-physical and sublingual immunotherapy with a monomeric allergoid in very young children. 11421908.
immunological properties. Int Arch Allergy Immunol. 2008;145(3):224-30. Epub 2007 Allergy. 2005 Jan;60(1):133. PubMed PMID: 15575951.
5: Liccardi G, Dente B, Restani P, Senna G, Falagiani P, Ballabio C, D'Amato G. Oct 3. PubMed PMID: 17914274.
Respiratory allergy induced by exclusive polysensitization to serum albumins of 45: Arena A, Cislaghi C, Falagiani P. Anaphylactic reaction to the ingestion of
furry animals. Eur Ann Allergy Clin Immunol. 2010 Jun;42(3):127-30. PubMed PMID: 30: Marogna M, Falagiani P, Bruno M, Massolo A, Riva G. The allergic march in raw onion. A case report. Allergol Immunopathol (Madr). 2000 Sep-Oct;28(5):287-9.
20648777. 18: Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous pollinosis: natural history and therapeutic implications. Int Arch Allergy PubMed PMID: 11270091.
reactions due to ASA-NSAIDs intolerance. Allergol Immunopathol (Madr). 2007 Immunol. 2004 Dec;135(4):336-42. Epub 2004 Nov 24. PubMed PMID: 15564776.
Jul-Aug;35(4):126-9. PubMed PMID: 17663920.
6: D'Anneo RW, Bruno ME, Falagiani P. Sublingual allergoid immunotherapy: a new 46: Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani
4-day induction phase in patients allergic to house dust mites. Int J 31: Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua P, Mistrello G, Canonica GW, Mariani G. Pharmacokinetics of an allergen and a
Immunopathol Pharmacol. 2010 Apr-Jun;23(2):553-60. PubMed PMID: 20646350. 19: Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and G. Quantitative assessment of the adherence to sublingual immunotherapy. J monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp
efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up Allergy Clin Immunol. 2004 Jun;113(6):1219-20. PubMed PMID: 15214362. Allergy. 2001 Jan;31(1):54-60. PubMed PMID: 11167951.
phase. Eur Ann Allergy Clin Immunol. 2006 Nov;38(9):310-2. PubMed PMID: 17191751.
7: Leonardi S, Arena A, Bruno ME, Cannaò PM, D'Anneo RW, Falagiani P, Gammeri E,
Mistrello G, Nicolini A, Ricciardi L, Valenti G, Longo R, La Rosa M. Olea 32: Hilger C, Thill L, Grigioni F, Lehners C, Falagiani P, Ferrara A, Romano C, 47: Angiola Crivellaro M, Senna G, Riva G, Cislaghi C, Falagiani P, Walter
sublingual allergoid immunotherapy administered with two different treatment 20: Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Stevens W, Hentges F. IgE antibodies of fish allergic patients cross-react with Canonica G, Passalacqua G. Pollen mixtures used as health food may be a harmful
regimens. Allergy Asthma Proc. 2010 Mar-Apr;31(2):e25-9. PubMed PMID: 20406589. Bruno ME, Falagiani P, Riva G. Clinical efficacy and safety of preseasonal frog parvalbumin. Allergy. 2004 Jun;59(6):653-60. PubMed PMID: 15147451. source of allergens. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):310-1.
sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic PubMed PMID: 11108445.
patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr).
8: Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, Riva G, 2006 Sep-Oct;34(5):194-8. PubMed PMID: 17064648. 33: Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy:
Braga M, Turi MC, Di Rienzo V, Petrarca C, Schiavone C, Di Gioacchino M. Oral lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol. 48: Senna GE, Andri G, Dama AR, Falagiani P, Andri L. Local nasal immunotherapy:
hyposensitization to nickel induces clinical improvement and a decrease in TH1 2003;13(4):228-31. PubMed PMID: 14989110. efficacy and tolerability of two different administration schedules in grass
and TH2 cytokines in patients with systemic nickel allergy syndrome. Int J 21: Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of pollen rhinitis. Allergol Immunopathol (Madr). 2000 Jul-Aug;28(4):238-42. PubMed
Immunopathol Pharmacol. 2010 Jan-Mar;23(1):193-201. PubMed PMID: 20378005. sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial PMID: 11022271.
hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch 34: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Analysis of the heat
Allergy Immunol. 2007;142(1):70-8. Epub 2006 Oct 2. PubMed PMID: 17016060. stability of lipid transfer protein from apple. J Allergy Clin Immunol. 2003
9: Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and Nov;112(5):1009-11. PubMed PMID: 14610497. 49: Corsico R, Falagiani P, Ariano R, Berra D, Biale C, Bonifazi F, Campi P,
tolerability of sublingual monomeric allergoid in tablets given without up-dosing Feliziani V, Frenguelli G, Galimberti M, Gallesio MT, Liccardi G, Loreti A,
to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. 22: Baruffini A, Pisati G, Russello M, Falagiani P. [Occupational allergic Marcer G, Marcucci F, Meriggi A, Minelli M, Nardelli R, Nardi G, Negrini CA, Papa
Eur Ann Allergy Clin Immunol. 2009 Dec;41(6):177-80. PubMed PMID: 20128231. IgE-mediated disease from Boletus edulis: case report]. Med Lav. 2005 35: Bagnasco M, Morbelli S, Altrinetti V, Falagiani P, Mariani G, Passalacqua G. G, Piu G, Pozzan M, D'Ambrosio FP, Riva G. An epidemiological survey on the
Nov-Dec;96(6):507-12. Italian. Erratum in: Med Lav. 2006 Jan-Feb;97(1):87. PubMed Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33-43. Review. allergological importance of some emerging pollens in Italy. J Investig Allergol
PMID: 16983976. PubMed PMID: 12947990. Clin Immunol. 2000 May-Jun;10(3):155-61. PubMed PMID: 10923590.
10: Burastero SE, Mistrello G, Paolucci C, Breda D, Roncarolo D, Zanotta S,
Falagiani P. Clinical and immunological correlates of pre-co-seasonal sublingual
immunotherapy with birch monomeric allergoid in patients with allergic 23: Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I, 36: Ballero M, Ariu A, Falagiani P. Allergy to Ailanthus altissima (tree of 50: Romano C, Ferrara A, Falagiani P. A case of allergy to globe artichoke and
rhinoconjunctivitis. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):343-52. Majani G, Falagiani P, Bruno M, Canonica GW. Randomized double-blind controlled heaven) pollen. Allergy. 2003 Jun;58(6):532-3. PubMed PMID: 12757458. other clinical cases of rare food allergy. J Investig Allergol Clin Immunol. 2000
PubMed PMID: 19505388. study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due 37: Mistrello G, Roncarolo D, Zanoni D, Zanotta S, Amato S, Falagiani P, Ariano Mar-Apr;10(2):102-4. PubMed PMID: 10879999.
to mites. Allergy. 2006 Jul;61(7):849-54. PubMed PMID: 16792583. R. Allergenic relevance of Cupressus arizonica pollen extract and biological
characterization of the allergoid. Int Arch Allergy Immunol. 2002
11: Di Gioacchino M, Perrone A, Petrarca C, Di Claudio F, Mistrello G, Falagiani Dec;129(4):296-304. PubMed PMID: 12483034. 51: Romano C, Ferrara AM, Cislaghi C, Falagiani P. Food allergy to frog. Allergy.
P, Dadorante V, Verna N, Braga M, Ballone E, Cavallucci E. Early cytokine 24: Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, 2000 Jun;55(6):584-5. PubMed PMID: 10858996.
modulation after the rapid induction phase of sublingual immunotherapy with mite Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy
monomeric allergoids. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):969-76. with Dermatophagoides monomeric allergoid down-regulates allergen-specific 38: Di Rienzo V, Falagiani P, Frati F, Sensi L, Marcucci F. Unusual IgE-mediated
PubMed PMID: 19144282. immunoglobulin E and increases both interferon-gamma- and allergy to fish bait. Allergy. 2002 Sep;57(9):869-70. PubMed PMID: 12169198. 52: Falagiani P. Intranasal immunotherapy. Allergy. 1999;54 Suppl 58:53-5.
interleukin-10-production. Clin Exp Allergy. 2006 Mar;36(3):261-72. PubMed PMID: Review. PubMed PMID: 10735653.
16499636.
12: Liccardi G, Passalacqua G, Falagiani P, Russo M, D'Amato G. The effect of 55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G. 39: Meglio P, Plantamura M, Arabito E, Falagiani P, Torre A, Rossi P. Does SIT to
multiple allergens on histamine release in vivo assessed by skin prick test. Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999 Der p protect from snail sensitization? Allergy. 2002 Sep;57(9):868-9. PubMed 53: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. True
Allergy. 2008 Nov;63(11):1559-60. PubMed PMID: 18925893. Jun;54(6):643-5. PubMed PMID: 10435484. PMID: 12169197. monosensitivity to a tropical sole. Allergy. 1999 Nov;54(11):1228-9. PubMed PMID:
10604565.

3. 54: Crimi E, Voltolini S, Minale P, Falagiani P. Value of immunoglobulin E 68: Zardi O, Zardi EM, Falagiani P, Zardi DM, Zardi MC, Barduagni F, Barduagni O. 82: D'Amato G, Gentili M, Russo M, Mistrello G, Saggese M, Liccardi G, Falagiani 95: Moscato G, Dellabianca A, Falagiani P, Mistrello G, Rossi G, Rampulla C.
density in predicting nasal and bronchial response to inhaled allergens in [Subcutaneous human dirofilariasis]. Pathologica. 1997 Feb;89(1):31-5. Review. P. Detection of Parietaria judaica airborne allergenic activity: comparison Inhaled furosemide prevents both the bronchoconstriction and the increase in
rhinitic and asthmatic subjects with multiple sensitizations. Clin Exp Allergy. Italian. PubMed PMID: 9312730. between immunochemical and morphological methods including clinical evaluation. neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in
1999 Dec;29(12):1663-70. PubMed PMID: 10594543. Clin Exp Allergy. 1994 Jun;24(6):566-74. PubMed PMID: 7922776. asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561-6. PubMed PMID: 2001067.
69: Canonica GW, Passalacqua G, Mariani G, Motta C, Bartolomei M, Mistrello G,
55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G. Falagiani P, Bagnasco M. Oral routes for immunotherapy: clinical efficacy and 83: Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified par j I 96: Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in
Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999 kinetics of the allergen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf allergen from P judaica pollen and its rate of absorption in rats. Immunol Lett. serum after intranasal treatment of normal rabbits with P. judaica extract.
Jun;54(6):643-5. PubMed PMID: 10435484. A M. 1997;(91):56-64; discussion 64-7. Review. PubMed PMID: 9383892. 1994 Apr;40(1):31-6. Erratum in: Immunol Lett 1994 Jul;41(2-3):291. PubMed PMID: Allergy. 1991 Jan;46(1):52-8. PubMed PMID: 2018209.
7927511.
56: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of 70: Falagiani P, Mistrello G. Pharmacokinetics of allergens after local 84: Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello 97: Falagiani P. Thimerosal in standard antigenic extracts. Contact Dermatitis.
sesame seed-induced anaphylaxis. Allergy. 1999 May;54(5):526-7. PubMed PMID: administration. Allergy. 1997;52(33 Suppl):17-21. Review. PubMed PMID: 9188942. G, Falagiani P, Geraci D. cDNA cloning, expression and primary structure of Par 1989 Nov;21(5):354. PubMed PMID: 2620521.
10380788. jI, a major allergen of Parietaria judaica pollen. FEBS Lett. 1994 Mar
21;341(2-3):182-6. PubMed PMID: 8137937.
71: Liccardi G, Mistrello G, Noschese P, Falagiani P, D'Amato M, D'Amato G. Oral 98: Cocchiara R, Locorotondo G, Parlato A, Guarnotta G, Ronchi S, Albeggiani G,
57: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Cislaghi C, Falagiani P. A allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two Amoroso S, Falagiani P, Geraci D. Purification of Parj I, a major allergen from
new apple extract. Allergy. 1999 Jan;54(1):87-8. PubMed PMID: 10195370. cases with two different patterns of onset. Allergy. 1996 Dec;51(12):919-22. 85: Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D, Auquier P. Parietaria, judaica pollen. Int Arch Allergy Appl Immunol. 1989;90(1):84-90.
PubMed PMID: 9020420. Prevalence of patent and latent atopy among a general normal adult population in PubMed PMID: 2478488.
the south east of France by RAST investigation and correlation with circulating
58: Roncarolo D, Minale P, Mistrello G, Voltolini S, Falagiani P. Food allergy to total IgE levels. Allergol Immunopathol (Madr). 1993 Nov-Dec;21(6):211-9. PubMed
Boletus edulis. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):850-1. PubMed PMID: 72: D'Amato G, Russo M, Liccardi G, Saggese M, Gentili M, Mistrello G, D'Amato M, PMID: 8160568. 99: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,
9648715. Falagiani P. Comparison between outdoor and indoor airborne allergenic activity. Riva G, Bolzacchini E. Micropreparative-scale enrichment of some allergenic
Ann Allergy Asthma Immunol. 1996 Aug;77(2):147-52. PubMed PMID: 8760781. components of Parietaria pollen extract. J Chromatogr. 1988 Jul 27;446:179-85.
86: Caneva E, Di Gennaro P, Farina F, Orlandi M, Rindone B, Falagiani P. PubMed PMID: 3209654.
59: Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local Synthesis and characterization of a penicillin-poly(L-lysine) which recognizes
immunotherapy: pharmacokinetics and efficacy. Allergy. 1998 May;53(5):477-84. 73: Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. human IgE anti-penicillin antibodies. Bioconjug Chem. 1993 Sep-Oct;4(5):309-13.
Review. PubMed PMID: 9636806. Monomeric chemically modified allergens: immunologic and physicochemical PubMed PMID: 8274512. 100: Genchi C, Falagiani P, Riva G, Tinelli M, Brunello F, Boero M, Almaviva M.
characterization. Allergy. 1996 Jan;51(1):8-15. PubMed PMID: 8721522. IgE and IgG antibodies in Toxocara canis infection. A clinical evaluation. Ann
Allergy. 1988 Jul;61(1):43-6. PubMed PMID: 3389570.
60: Mistrello G, Gentili M, Roncarolo D, Antoniotti P, Ottoboni F, Falagiani P. 87: Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal
Dot immunobinding assay for detection of mite antigens in house-dust samples. J 74: Andri L, Senna G, Betteli C, Givanni S, Andri G, Dimitri G, Falagiani P, immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder
Med Entomol. 1998 Mar;35(2):143-7. PubMed PMID: 9538574. Mezzelani P. Local nasal immunotherapy with extract in powder form is effective extract. J Allergy Clin Immunol. 1993 May;91(5):987-96. PubMed PMID: 8491949. 101: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,
and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol. Riva G, Bolzacchini E. Analysis of allergenic components of a Parietaria judaica
1996 Jan;97(1 Pt 1):34-41. PubMed PMID: 8568135. pollen extract by chromatographic methods for the evaluation of purification
61: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of 88: Ariano R, Panzani RC, Falagiani P, Chiapella M, Augeri G. Respiratory allergy procedures. J Chromatogr. 1988 Jul 1;444:209-18. PubMed PMID: 3204131.
garlic allergy. J Allergy Clin Immunol. 1998 Mar;101(3):427-8. PubMed PMID: to the pollen of Mercurialis annua (Euphorbiaceae). Ann Allergy. 1993
9525465. 75: Andri L, Senna G, Andri G, Dama A, Givanni S, Betteli C, Dimitri G, Falagiani Mar;70(3):249-54. PubMed PMID: 8452320.
P, Mezzelani P. Local nasal immunotherapy for birch allergic rhinitis with 102: Bolzacchini E, Di Gregorio G, Nali M, Rindone B, Tollari S, Falagiani P,
extract in powder form. Clin Exp Allergy. 1995 Nov;25(11):1092-9. PubMed PMID: Riva G, Crespi G. Purification and molecular weight studies on the components of
62: Pisati G, Baruffini A, Bernabeo F, Falagiani P. Environmental and clinical 8581842. 89: Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P. a Parietaria pollen extract. Allergy. 1988 Jan;43(1):53-9. PubMed PMID: 3344935.
study of latex allergy in a textile factory. J Allergy Clin Immunol. 1998 Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol. 1993
Mar;101(3):327-9. PubMed PMID: 9525447. Mar;20(3):489-94. PubMed PMID: 8386767.
76: Mistrello G, Gentili M, Falagiani P, Roncarolo D, Riva G, Tinelli M. Dot 103: Amoroso S, Cocchiara R, Locorotondo G, Parlato A, Lampiasi N, Albeggiani G,
immunobinding assay as a new diagnostic test for human hydatid disease. Immunol Falagiani P, Geraci D. Antigens of Euparipha pisana (snail). I. Identification of
63: Coppola V, Veronesi A, Indraccolo S, Calderazzo F, Mion M, Minuzzo S, Lett. 1995 Jul-Aug;47(1-2):79-85. PubMed PMID: 8537105. 90: Panzani RC, Falagiani P, Riva G, Mercier P, Delord. Screening for IgE allergens by means of in vivo and in vitro analysis. Int Arch Allergy Appl
Esposito G, Mauro D, Silvestri B, Gallo P, Falagiani P, Amadori A, Chieco-Bianchi mediated allergy among people working in the Marseilles harbour. Allergol Immunol. 1988;85(1):69-75. PubMed PMID: 2448245.
L. Lymphoproliferative disease in human peripheral blood mononuclear Immunopathol (Madr). 1993 Jan-Feb;21(1):25-9. PubMed PMID: 8328353.
cell-injected SCID mice. IV. Differential activation of human Th1 and Th2 77: Romano C, Sulotto F, Piolatto G, Ciacco C, Capellaro E, Falagiani P,
lymphocytes and influence of the atopic status on lymphoma development. J Constable DW, Verga A, Scansetti G. Factors related to the development of 104: Tinelli M, Falagiani P, Riva G, Genchi C. RAST and ELISA in three
Immunol. 1998 Mar 1;160(5):2514-22. PubMed PMID: 9498797. sensitization to green coffee and castor bean allergens among coffee workers. 91: Andri L, Senna GE, Betteli C, Givanni S, Andri G, Falagiani P, Lugo G. Local autochthonous parasitic infections in Italy: toxocariasis, hydatidosis and
Clin Exp Allergy. 1995 Jul;25(7):643-50. PubMed PMID: 8521183. nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled fascioliasis. Boll Ist Sieroter Milan. 1987;66(1):38-45. PubMed PMID: 3620121.
study. Allergy. 1992 Aug;47(4 Pt 1):318-23. PubMed PMID: 1443452.
64: Passalacqua G, Albano M, Pronzato C, Riccio AM, Scordamaglia A, Falagiani P,
Canonica GW. Long-term follow-up of nasal immunotherapy to Parietaria: clinical 78: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in 105: Sgambato F, Pedicini A, De Rienzo D, Falagiani P. [Inhalation allergy to fly
and local immunological effects. Clin Exp Allergy. 1997 Aug;27(8):904-8. PubMed a coffee-processing factory. Int Arch Allergy Immunol. 1995 92: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello larva. A clinical case]. Boll Ist Sieroter Milan. 1987;66(5):411-5. Italian.
PMID: 9291287. May-Jun;107(1-3):443-4. PubMed PMID: 7613207. G, Sondergaard I. Purification of Phleum pratense pollen extract by PubMed PMID: 3449104.
immunoaffinity chromatography and high-performance ion-exchange chromatography. J
Chromatogr. 1991 Jul 12;548(1-2):229-34. PubMed PMID: 1939423. 106: Boner AL, Vallone G, Bennati D, Falagiani P, Gaburro D. Simplified spinhaler
65: Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, 79: Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local intranasal method for antigen-specific bronchoprovocation in children with bronchial asthma.
Mistrello G, Canonica GW. Absorption and distribution kinetics of the major immunotherapy with allergen in powder in atopic patients sensitive to Parietaria I. Ann Allergy. 1986 Nov;57(5):363-6. PubMed PMID: 3777536.
Parietaria judaica allergen (Par j 1) administered by noninjectable routes in officinalis pollen. J Investig Allergol Clin Immunol. 1995 May-Jun;5(3):126-32. 93: Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, 107: Brunello F, Falagiani P, Genchi C. Enzyme immunoassay (ELISA) for the
healthy human beings. J Allergy Clin Immunol. 1997 Jul;100(1):122-9. PubMed PMID: PubMed PMID: 7582157. Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis detection of specific IgG antibodies to Toxocara canis ES antigens. Boll Ist
9257796. and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T Sieroter Milan. 1986;65(1):54-60. Erratum in: Boll Ist Sieroter Milan
80: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in cells with stable and opposite (type 1 T helper or type 2 T helper) profile of 1986;65(5):following 445. PubMed PMID: 3718679.
66: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Falagiani P. a coffee processing factory. Allergol Immunopathol (Madr). 1995 cytokine production. J Clin Invest. 1991 Jul;88(1):346-50. PubMed PMID: 1829097;
Exercise-induced egg anaphylaxis. Allergy. 1997 Jun;52(6):687-9. PubMed PMID: Jan-Feb;23(1):29-34. PubMed PMID: 7631592. PubMed Central PMCID: PMC296040. 08: Genchi C, Tinelli M, Brunello F, Falagiani P. Serodiagnosis of ocular
9226076. toxocariasis: a comparison of specific IgE and IgG. Trans R Soc Trop Med Hyg.
1986;80(6):993-4. PubMed PMID: 3603652.
81: Falagiani P, Mistrello G, Rapisarda G, Festa A, Cislaghi C, Zanoni D. 94: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello
67: Asero R, Mistrello G, Falagiani P. Oral allergy syndrome from pork. Allergy. Evaluation of allergenic potency by REAST inhibition. A new tool for the G, Sondergaard I. Allergenic fragments in Parietaria judaica pollen extract. J 109: Falagiani P, Cavallone E, Nali M, Rindone B, Tollari S, Crespi G. Aqueous
1997 Jun;52(6):684-6. PubMed PMID: 9226073. standardization of allergenic extracts. J Immunol Methods. 1994 Aug Chromatogr. 1991 Apr 12;542(2):337-44. PubMed PMID: 1715346. size-exclusion analysis of Parietaria pollen extracts. J Chromatogr. 1985 Jun
1;173(2):181-90. PubMed PMID: 8046253. 28;328:425-31. PubMed PMID: 4030974.

4. An impressively productive scientific mind

5. Il dosaggio radio-immunologico delle reagine
del secreto nasale.
• Boll Soc Ital Biol Sper.
• 1977 Feb 15 ; 53(3):188-92.
• Crifò S, Falagiani P, Filiaci F, Andriani G.

7. The author of numerous books

8. Concept of the
monomeric allergoid

11. The novel view
on specific
immunotherapy

12. The first specific sublingual immuntherapy
with allergoids available as tablets & drops
The Idea:
To combine the advantages of
allergoids together with the
sublingual route into a better
effective and more safe
Immunotherapy

13. Chemical modification of
residual peripheral
aminoacid-sequences
Reduced IgE binding affinity
Maintained
conformation
for T-cell-binding

14. The first specific sublingual immuntherapy
with allergoids available as tablets & drops
Sublingual Allergoides Allergens
the modified molecule resists to The unmodified molecule is destroyed
enzymatic coupling and remains intact. by the attack of enzymes.

15. The first specific sublingual immuntherapy
with allergoids available as tablets & drops
The novel approach
Monomerization
(Monoid)
Allergen extracts are chemically transformed, the
Carbamylation, to replace parts of the protein
components, and to maintain the molecular dimensions.

16. Characterization of the sublingual
carbamylated allergoid (Monoid)
1-Reduction of the Allergenicity
2-Maintenance of the Antigenicity
3-Maintenance of the Molecular Dimension
4-Resistance against Enzymatic Digestion
5-Absence of Toxicity

17. Concept Overview
Allergenicit Proteine Enzymatic
Allergen Type Antigenity
y Structure Protection
Modified,
Reduced complex
Monoid Maintained Shown
(targeted) („Segments
cut“)
Native Allergen Maintained Maintained Nativ, complex Not shown
Reduced
Reduced
Allergoid (Not Polymerized Not shown
(targeted)
targeted)

18. Route of action in the oromucosal and
gastrointestinal system
APC Lymphozytes
oral Lymphatic
mucosa system
Allergoid systemic clinical
SLIT circulation results
gastrointestinal capillaries
mucosa

19. Pharmacokinetics
& Immunology

20. Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G..
Clinical Immunology Service, DIMI, Genoa, Italy
Objective
To study the pharmacokinetics
in allergic volunteers
of allergoid sublingual immunotherapy
in oromucosal tablets

21. Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G..
Clinical Immunology Service, DIMI, Genoa, Italy
Methods
Radiolabelled monomeric allergoid and native allergen, administered to 8
allergic pts and 1 non atopic, were detected by scintigraphic acquisitions.
Plasma radioactivity was measured at different intervals.
Results
The increased resistance to gastrointestinal enzymatic degradation can explain
the high absorption of the monomeric allergoid and its appearance in the
bloodstream.
The local persistence of the monomeric allergoid and allergen may involve the
mucosal immunity in the mechanism of action of antiallergic vaccination.

22. Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al.
Clinical Immunology Service, DIMI, Genoa, Italy
5-
Sublingual allergoids
Plasmatic Radioactivity
in form of tablets
3-
Native Allergens
in liquid solution
1- Native Allergens
in form of tablets
I I I I
1 2 5 Hrs after application 15
ALLERGO Kinetics

23. Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al.
Clinical Immunology Service, DIMI, Genoa, Italy
Conclusions
 Systemic absorption
 Mucosal immunity involvement

24. Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,
Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Objective
To show the immunological effects of a sublingual carbamylated allergoid.
Methods
25 pts: with rhinitis / asthma to Der p1, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. 1,5 years of treatment.
Treated group: 12 Lais Der p1
Placebo group: 13

25. Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results
the sublingual allergoid increases the
production of the cytokines IL-10 & IFN-

26. Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results
the sublingual allergoid reduces the
production of spezific IgE

27. Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Conclusion
Clear immunological effects have been shown under
treatment with a sublingual carbamylated allergoid.

28. DBPC Trials Results

29. Results from recent
(DBPC) Trials
Sublingual Allergoids
efficacy (subjective data)
• Reduction of symptoms of asthma
• Reduction of symptoms of rhinoconjunctivitis
• Reduction of symptomatic medication

30. Results from recent
(DBPC) Trials
Sublingual allergoids
efficacy (objective data)
Efficacy was assessed using objective measurements:
• increase of the provocative dose
specifically in nasal provocation test
unspecifically with Metacholine

31. Results from recent
(DBPC) Trials
Sublingual allergoids
Safety
The safety of treatment is supported by
numerous published clinical studies.
The sublingual allergoid, the Monoid, has
demonstrated its safety also in patients with
Oral Allergy Syndrome (OAS).

32. Results from recent
(DBPC) Trials
Sublingual allergoids
Tolerability
Tolerability is supported by data from numerous
clinical trials

33. Results from recent
(DBPC) Trials
Sublingual allergoids
Compliance
Compliance, adherence with the treatment is excellent as
demonstrated by:
•Pill count in clinical trials.
•Repetitive prescription in real life studies.

34. Results from recent
(DBPC) Trials

35. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Material & methods
48 pts: 8 yrs mean age, Rhinoconjunctivitis/Asthma
to Grass. DBPC study. Positive anamnesis,
SPT and RAST. ECP, symptoms, drug score
and Compliance recorded.
Protocol: preseasonal scheduling.
IT treated: 24 Lais Grass.
Drug treated: 20 (4 drop out).

36. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Results
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores in pollen season
Good compliance.
No differences in placebo group.

37. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
15 - p<0.05
score
10 - NS
NS
5- p<0.05
NS
I I I I I
Symptome Symptome Symptome Symptome Rescue medication
NASAL OCULAR BRONCHIAL TOTAL
Reduction of total symptom score
during treatment with sublingual allergoids  vs Placebo 
During the grass pollen season.

38. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Conclusions
The preseasonal course with Lais Grass
as Allergoid SLIT:
is effective in the reduction of respiratory
symptoms of children,
in particular asthma, within 3,5 months

39. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Material & Methods
33 pts: with rhinitis / asthma to Phl p5, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo
Treated group: 17 Lais 3-Gras Mix
Placebo group: 16

40. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Design

41. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Improvement of the nasal provocation test
Results Reduction of rhinoconjunctivitis symptoms

42. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Reduction of steroid consumption
Results

43. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Conclusions
SLIT in gras allergic patients is effective and reduces
single symptoms between 40 - 60 %
and
co-medication (steroids) vs. placebo up to 80%
(at pollen peak)

44. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Material & methods
30 pts: with rhinitis / asthma to Par j, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. Dec.92 to Jul.95.
Treated group: 15 Lais Par j (1 drop out).
Placebo group: 15

45. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Results
Statistically significant differences in the
Allergoid SLIT treated group:
Reduced symptoms score (in particular during pollen season).
Reduced medication score.
Increased threshold dose with Allerkin Test.
Increased threshold dose with Methacholine Lofarma.
No differences in placebo group.

46. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Conclusions
Hyposensitization with Parietaria pollen as
Allergoid SLIT
is a safe and efficaceous vaccine
which may be used in children and adults.

47. The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy
Material & methods
20 pts: per. rhinoconjunctivitis to Der, positive to
anamnesis, prick, RAST and SCPT.
Inflammatory-cells and ICAM-1 and
serum inflam. markers (ECP) recorded.
Protocol: double blind vs placebo. Apr.94 to Mar.96.
Treated group: 10 Lais Der p&f.
Placebo group: 10 (1 drop out).

48. The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy
Results
Statistically significant differences in
The monomeric Allergoid SLIT group:
Reduced symptom & medication scores.
Reduced inflammatory infiltration and ICAM-1 expression.
Reduced MPI, the Minimal Persistent Inflammation.
No differences in placebo group.

49. The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy
NEUTROFILE
EOSINOFILE
ICAM 1
0.001
3- p<0.001 3- 10 -
0.001
NS
NS
1- NS
1- 5-
I I I I I I
T0 24 Months T0 24 Months T0 24 Months
Reduction of inflammation
After 24 months of treatment with sublingual allergoids vs Placebo 
Demonstrated by conjunctival provocation test

50. The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy
Conclusions
Hyposensitization with Dermatophagoides
as Allergoid SLIT:
l reduces the allergic inflammation
l is safe and clinically effective.

52. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
Material & methods
39 pts: Rhinoconjunctivitis / Asthma (50%) to Par.
Positive anamnesis, SPT, PFT and SNPT.
Serum inflam. markers (ECP) recorded.
Symptoms & Drug Score, QoL.
Protocol: clustered treatment according to Data Sheet.
IT treated: 27 Lais Par.
Drug treated: 12 (3 drop out).

53. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
Results
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores.
Improved Quality of Life, assessed by questionnaire.
Good compliance, over 80% .
No differences in placebo group.

54. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
Conclusions
The Clustered Treatment with Parietaria as
Allergoid SLIT:
l is a suitable treatment when it is too
late to start a conventional scheduling
l is well tolerated and safe.

55. Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
Objective
To study the safety of ultra
rush SLIT with four commercial
products in allergic patients.

56. Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
Material & Methods
Ninety-one allergic patients with rhino-conjunctivitis
and/or asthma.
Prospective observational, 36 months follow-up study.
Maintenance phase from Dec 2001 to Mar 2002.
Subdivided in three groups, one was administered the
sublingual allergoid, the others, injective I.T. and drugs.

57. Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
Results
One adverse event, after 300 IR/ml,
disappeared when adjusted at 30 IR.
No adverse events were noted after
administration of the allergoid SLIT.

61. Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years prospective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy
Objective
To evaluate the efficacy, tolerability
and adherence to treatment of
allergoid sublingual immunotherapy
(I.T.), in comparison with injective
I.T. and drugs.

62. Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy
Material & Methods
One hundred and ten allergic patients with rhino-
conjunctivitis and/or asthma.
Subdivided in three groups, one was administered the
sublingual allergoid, the others injective I.T. and drugs.
Prospective, observational, 36 months follow-up study.
Allergens: pollens and House Dust Mite.

63. Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy
Results
Sublingual allergoid I.T. was
considered by patients and doctors to
be better than the other two therapies
(p<0.0001) as far as efficacy,
tolerability and patient’s compliance
concern.

64. Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy
Conclusions
Allergoid Sublingual I.T. was
positively appreciated by both
patients and physicians for its
simplicity of use, good efficacy and
the high degree of safety offered.

66. SLIT with monomeric allergoid
• Effective in rhinoconjunctivitis and asthma
• Impeccable safety also in risk populations
• Perfectly tolerable in adults and children
• Outstanding compliance and adherence
• Internationally accepted by
– The Paul Ehrlich Institute

67. Paolo Falagiani
1947 - 2011
Thank you for the
attention